Lupin has entered into the prescription dermatology segment in Brazil with the launch of Fillerina and Recrexina under the Lupin High-End Skin Science umbrella.
Valued at USD 28 billion, Brazil is the world's 6th largest pharmaceutical market, driven by growing public health expenditure and increasing household income. The dermatology segment in Brazil, worth USD 1.5 billion, and growing at 10% (CAGR) is one of the fastest growing segments in the country.
Fillerina is a high-end anti-aging technology that incorporates a deep action innovative formulation to fill wrinkles and expression lines.
Its use of six different molecular weight hyaluronic acid molecules in the formulation combats signs of aging, with clinical evidence of a lifting and plumping effect and reduction in wrinkles.
Recrexina is a hair-growth formulation which stimulates natural hair growth in active and partially inactive follicles, through the use of a patented formulation of biostimulating molecules which preserve the stem cells in hair follicles. Its exclusive 5-way mechanism of action addresses the key factors that impact hair including hair bulb nutrition and reduction of 5-alpha reductase activity.
As part of the launch, Lupin has also launched a 360-degree communications campaign, focused on healthcare professionals, pharmacy chains and regional and national medical associations in Brazil.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)